Merck & Co. Inc. (MRK)

73.70
3.20 4.20
NYSE : Health Technology
Prev Close 76.94
Open 74.66
Day Low/High 73.02 / 75.47
52 Wk Low/High 65.25 / 92.64
Volume 6.20M
Avg Volume 13.18M
Exchange NYSE
Shares Outstanding 2.54B
Market Cap 181.93B
EPS 3.80
P/E Ratio 20.20
Div & Yield 2.44 (3.15%)

Latest News

Jim Cramer: Do You Really Want to Sell Now?

Jim Cramer: Do You Really Want to Sell Now?

The answer to that question depends on several factors, so let's break them down.

The Markets That Roared, China Trade, Travel Stocks Pain, Macy's Investor Day

The Markets That Roared, China Trade, Travel Stocks Pain, Macy's Investor Day

The timing of this morning's rally? Almost simultaneously news broke from both China and the UK of possible drugs to fight coronavirus.

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

These companies all could be strong -- even if the 2019 nCoV fear spreads.

Jim Cramer: I'm Dumbfounded Tesla's Stock Is Not Up Even More Than It Is

Jim Cramer: I'm Dumbfounded Tesla's Stock Is Not Up Even More Than It Is

This is a market that thrives on growth. Tesla has it in spades.

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.

Personalis Has Struggled Since Its IPO - Here's How I'd Play It

Personalis Has Struggled Since Its IPO - Here's How I'd Play It

The company has a collaboration with Merck, and there are far worse partners you could have when working in the cancer segment of biotech.

Advanced Micro Devices Is a Real Player and Here's How I'm Trading It

Advanced Micro Devices Is a Real Player and Here's How I'm Trading It

I have long been enamored with Lisa Su as a Chief Executive.

2 Potential Targets as Biotech Acquisition Activity Heats Up

2 Potential Targets as Biotech Acquisition Activity Heats Up

TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.

China Dealings, Global Trade, Updating 4 Stocks, Trading Apple: Market Recon

China Dealings, Global Trade, Updating 4 Stocks, Trading Apple: Market Recon

Does it tick the President off that it appears the Chinese would rather not give up in writing any unfair advantages in global trade that they have enjoyed for decades this close to a national election in the U.S.? Of course.

The Fed Today, What Could Go Wrong in December? Watching 4 Stocks: Market Recon

The Fed Today, What Could Go Wrong in December? Watching 4 Stocks: Market Recon

I do expect there to be some early to mid-December profit taking. But to get from here to year end without hitting some mid-month turbulence would be a pleasant surprise.

Jim Cramer: Here's the Good News About the U.S./China Trade Delay

Jim Cramer: Here's the Good News About the U.S./China Trade Delay

There are plenty of stocks that have been thrown away for several weeks because of a belief that the Fed and a trade deal will avoid a recession.

Merck Might Make Healthy Rally

Merck Might Make Healthy Rally

Here's how to get in on the trade if it can hold on a pullback to the Oct. 22; also if Facebook's price holds above $186, expect it to go higher.

Drug Companies Are a Political Football, Trading Amgen: Market Recon

Drug Companies Are a Political Football, Trading Amgen: Market Recon

The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.

Jim Cramer: Nothing's Changed, Except the Prices

Jim Cramer: Nothing's Changed, Except the Prices

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

Jim Cramer: Take the Billionaire Investors With a Grain of Salt

Jim Cramer: Take the Billionaire Investors With a Grain of Salt

Despite the rhetoric from on high, it is possible to find good stock picks in this market.

Jim Cramer: Demand Is Driving This Market to All-Time Highs

Jim Cramer: Demand Is Driving This Market to All-Time Highs

The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

Merck's Decline Today Looks Like an Opportunity to Buy the Dip

Merck's Decline Today Looks Like an Opportunity to Buy the Dip

Let's visit with the charts of MRK.

Jim Cramer: Lack of Individual Stock Pickers Has Led to This Equity Glut

Jim Cramer: Lack of Individual Stock Pickers Has Led to This Equity Glut

We don't have enough stock pickers or individuals to handle all the new stock that's been created. And It is trashing the cloud kings, among others.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

Jim Cramer: The Market Is Lapping Up These Stocks

Jim Cramer: The Market Is Lapping Up These Stocks

There are plenty of senior growth companies that can still move higher.

Jim Cramer: What Would Make a Good Stock in This Environment?

Jim Cramer: What Would Make a Good Stock in This Environment?

Let me give you the items I want to see before I bless buying anything in what has become a plain, out and out, treacherous market.

Buying Merck? Here's the One Technical Level to Watch

Buying Merck? Here's the One Technical Level to Watch

The longer-term picture of MRK is positive.

Jim Cramer: Watch for Stocks Reporting 'Not as Bad as Feared' Numbers

Jim Cramer: Watch for Stocks Reporting 'Not as Bad as Feared' Numbers

When you have an oversold market you've got a true coiled spring that can rally beyond where it might ordinary go on good news.

Merck Shares Could Trade Sideways Before Renewed Gains

Merck Shares Could Trade Sideways Before Renewed Gains

Let's visit with the charts and indicators to get another perspective.